Södertälje, Sweden

Johan Lindström


Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2011

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Johan Lindström: Innovator in Aβ-Related Pathologies

Introduction

Johan Lindström, an accomplished inventor based in Södertälje, Sweden, has made significant contributions to the field of pharmaceuticals. His innovative work focuses on the development of new compounds aimed at addressing serious health conditions associated with Aβ-related pathologies.

Latest Patents

Lindström holds a patent titled "Substituted isoindoles for the treatment and/or prevention of Aβ-related pathologies." This groundbreaking invention relates to novel compounds and their pharmaceutical compositions that target various disorders. The therapeutic methods developed by Lindström aim to treat or prevent numerous cognitive impairments, including Alzheimer's disease, mild cognitive impairment (MCI), and other related ailments.

Career Highlights

Johan Lindström's career is highlighted by his role at AstraZeneca AB, where he contributes to cutting-edge research and development. His innovative ideas and expertise play a crucial role in advancing the company's mission of improving patient outcomes through effective medication.

Collaborations

Throughout his career, Lindström has collaborated with notable colleagues in the field, including Jörg Holenz and Sofia Karlström. These partnerships have fostered an environment of creativity and innovation, enabling the development of significant therapeutic strategies.

Conclusion

Johan Lindström's dedication to researching and developing solutions for Aβ-related pathologies exemplifies the spirit of innovation. His patent represents a meaningful advancement in medical science, promising better treatment options for individuals affected by cognitive decline and related diseases. Through his work at AstraZeneca AB and collaboration with talented coworkers, Lindström continues to push the boundaries of pharmaceutical innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…